Camp4 Therapeutics Corp. Financials
This page shows Camp4 Therapeutics Corp. (CAMP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Camp4 Therapeutics Corp. has an operating margin of -1502.4%, meaning the company retains $-1502 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -8142.3% the prior year.
Camp4 Therapeutics Corp.'s revenue surged 436.5% year-over-year to $3.5M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Camp4 Therapeutics Corp. carries a low D/E ratio of 1.47, meaning only $1.47 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.35, Camp4 Therapeutics Corp. holds $7.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Camp4 Therapeutics Corp. generated -$29.6M in operating cash flow, capex of $279K consumed most of it, leaving -$29.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Camp4 Therapeutics Corp. generates a -168.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -82.0% the prior year.
Camp4 Therapeutics Corp. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Camp4 Therapeutics Corp. generates $0.37 in operating cash flow (-$29.6M OCF vs -$80.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Camp4 Therapeutics Corp. generated $3.5M in revenue in fiscal year 2025. This represents an increase of 436.5% from the prior year.
Camp4 Therapeutics Corp.'s EBITDA was -$50.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.9% from the prior year.
Camp4 Therapeutics Corp. reported -$80.4M in net income in fiscal year 2025. This represents a decrease of 55.2% from the prior year.
Camp4 Therapeutics Corp. earned $-2.65 per diluted share (EPS) in fiscal year 2025. This represents an increase of 76.0% from the prior year.
Cash & Balance Sheet
Camp4 Therapeutics Corp. generated -$29.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 35.2% from the prior year.
Camp4 Therapeutics Corp. held $109.5M in cash against $0 in long-term debt as of fiscal year 2025.
Camp4 Therapeutics Corp. paid $0.00 per share in dividends in fiscal year 2025.
Camp4 Therapeutics Corp. had 52M shares outstanding in fiscal year 2025. This represents an increase of 157.4% from the prior year.
Margins & Returns
Camp4 Therapeutics Corp.'s operating margin was -1502.4% in fiscal year 2025, reflecting core business profitability. This is up 6639.9 percentage points from the prior year.
Camp4 Therapeutics Corp.'s net profit margin was -2298.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5644.9 percentage points from the prior year.
Camp4 Therapeutics Corp.'s ROE was -168.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 86.5 percentage points from the prior year.
Capital Allocation
Camp4 Therapeutics Corp. invested $38.2M in research and development in fiscal year 2025. This represents a decrease of 1.6% from the prior year.
Camp4 Therapeutics Corp. invested $279K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 36.7% from the prior year.
CAMP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $348K-56.2% | $795K-46.9% | $1.5M+74.5% | $858K | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $8.4M-10.7% | $9.4M-9.5% | $10.3M+1.9% | $10.1M | N/A | $9.7M+3.3% | $9.4M-3.6% | $9.7M |
| SG&A Expenses | $4.8M+3.7% | $4.6M+9.9% | $4.2M+9.7% | $3.8M | N/A | $3.8M+16.5% | $3.3M+4.4% | $3.1M |
| Operating Income | -$12.8M+6.4% | -$13.7M-4.8% | -$13.0M+0.5% | -$13.1M | N/A | -$13.5M-6.7% | -$12.7M+1.7% | -$12.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$40.3M-166.8% | -$15.1M-20.0% | -$12.6M-1.2% | -$12.4M | N/A | -$13.5M-7.3% | -$12.6M-0.9% | -$12.5M |
| EPS (Diluted) | N/A | $-0.55+11.3% | $-0.620.0% | $-0.62 | N/A | $-24.19+7.0% | $-26.00+2.1% | $-26.57 |
CAMP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $117.8M+36.4% | $86.4M+68.5% | $51.3M-18.3% | $62.8M-19.8% | $78.3M+266.5% | $21.4M | N/A | N/A |
| Current Assets | $114.1M+46.8% | $77.7M+89.1% | $41.1M-20.5% | $51.7M-22.2% | $66.4M+1106.1% | $5.5M | N/A | N/A |
| Cash & Equivalents | $109.5M+45.5% | $75.3M+92.7% | $39.1M-20.8% | $49.3M-23.0% | $64.0M+2433.2% | $2.5M-82.2% | $14.2M-50.3% | $28.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $1.0M | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $70.1M+152.8% | $27.7M+145.6% | $11.3M+0.8% | $11.2M-26.1% | $15.2M-91.6% | $180.3M | N/A | N/A |
| Current Liabilities | $15.5M+96.3% | $7.9M+7.7% | $7.3M+13.9% | $6.4M-32.9% | $9.6M-18.9% | $11.8M | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $47.7M-18.7% | $58.7M+46.7% | $40.0M-22.5% | $51.6M-18.3% | $63.1M+139.7% | -$159.0M-8.1% | -$147.1M-8.7% | -$135.3M |
| Retained Earnings | -$292.2M-16.0% | -$251.9M-6.4% | -$236.8M-5.6% | -$224.2M-5.9% | -$211.8M-6.7% | -$198.5M | N/A | N/A |
CAMP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.3M+156.1% | -$11.2M-8.5% | -$10.3M+27.6% | -$14.3M-26.6% | -$11.3M-16.5% | -$9.7M+27.9% | -$13.4M-20.6% | -$11.1M |
| Capital Expenditures | $0 | $0 | $0-100.0% | $279K+6.1% | $263K | $0-100.0% | $163K+986.7% | $15K |
| Free Cash Flow | $6.3M+156.1% | -$11.2M-8.5% | -$10.3M+29.0% | -$14.6M-26.1% | -$11.6M-19.2% | -$9.7M+28.7% | -$13.6M-21.9% | -$11.2M |
| Investing Cash Flow | $0-100.0% | $36K | $0+100.0% | -$279K-6.1% | -$263K | $0+100.0% | -$163K-986.7% | -$15K |
| Financing Cash Flow | $28.6M-39.7% | $47.4M+65711.1% | $72K+147.7% | -$151K-100.2% | $73.1M+19028.0% | -$386K+52.5% | -$812K-302.0% | -$202K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CAMP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -3671.3%-1954.2pp | -1717.1%-846.8pp | -870.3%+656.5pp | -1526.8% | N/A | N/A | N/A | N/A |
| Net Margin | -11575.9%-9676.6pp | -1899.3%-1058.4pp | -840.8%+608.3pp | -1449.1% | N/A | N/A | N/A | N/A |
| Return on Equity | -84.5%-58.7pp | -25.7%+5.7pp | -31.5%-7.4pp | -24.1% | N/A | N/A | N/A | N/A |
| Return on Assets | -34.2%-16.7pp | -17.5%+7.1pp | -24.6%-4.7pp | -19.8% | N/A | -63.1% | N/A | N/A |
| Current Ratio | 7.35-2.5 | 9.83+4.2 | 5.60-2.4 | 8.02+1.1 | 6.92+6.5 | 0.47 | N/A | N/A |
| Debt-to-Equity | 1.47+1.0 | 0.47+0.2 | 0.28+0.1 | 0.22-0.0 | 0.24+1.4 | -1.13 | N/A | N/A |
| FCF Margin | 1808.3%+3219.3pp | -1410.9%-720.0pp | -690.9%+1006.6pp | -1697.5% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Camp4 Therapeutics Corp.'s annual revenue?
Camp4 Therapeutics Corp. (CAMP) reported $3.5M in total revenue for fiscal year 2025. This represents a 436.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Camp4 Therapeutics Corp.'s revenue growing?
Camp4 Therapeutics Corp. (CAMP) revenue grew by 436.5% year-over-year, from $652K to $3.5M in fiscal year 2025.
Is Camp4 Therapeutics Corp. profitable?
No, Camp4 Therapeutics Corp. (CAMP) reported a net income of -$80.4M in fiscal year 2025, with a net profit margin of -2298.5%.
What is Camp4 Therapeutics Corp.'s EBITDA?
Camp4 Therapeutics Corp. (CAMP) had EBITDA of -$50.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Camp4 Therapeutics Corp.'s operating margin?
Camp4 Therapeutics Corp. (CAMP) had an operating margin of -1502.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Camp4 Therapeutics Corp.'s net profit margin?
Camp4 Therapeutics Corp. (CAMP) had a net profit margin of -2298.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Camp4 Therapeutics Corp.'s return on equity (ROE)?
Camp4 Therapeutics Corp. (CAMP) has a return on equity of -168.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Camp4 Therapeutics Corp.'s free cash flow?
Camp4 Therapeutics Corp. (CAMP) generated -$29.8M in free cash flow during fiscal year 2025. This represents a 35.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Camp4 Therapeutics Corp.'s operating cash flow?
Camp4 Therapeutics Corp. (CAMP) generated -$29.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Camp4 Therapeutics Corp.'s total assets?
Camp4 Therapeutics Corp. (CAMP) had $117.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Camp4 Therapeutics Corp.'s capital expenditures?
Camp4 Therapeutics Corp. (CAMP) invested $279K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Camp4 Therapeutics Corp. spend on research and development?
Camp4 Therapeutics Corp. (CAMP) invested $38.2M in research and development during fiscal year 2025.
What is Camp4 Therapeutics Corp.'s current ratio?
Camp4 Therapeutics Corp. (CAMP) had a current ratio of 7.35 as of fiscal year 2025, which is generally considered healthy.
What is Camp4 Therapeutics Corp.'s debt-to-equity ratio?
Camp4 Therapeutics Corp. (CAMP) had a debt-to-equity ratio of 1.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Camp4 Therapeutics Corp.'s return on assets (ROA)?
Camp4 Therapeutics Corp. (CAMP) had a return on assets of -68.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Camp4 Therapeutics Corp.'s cash runway?
Based on fiscal year 2025 data, Camp4 Therapeutics Corp. (CAMP) had $109.5M in cash against an annual operating cash burn of $29.6M. This gives an estimated cash runway of approximately 44 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Camp4 Therapeutics Corp.'s Piotroski F-Score?
Camp4 Therapeutics Corp. (CAMP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Camp4 Therapeutics Corp.'s earnings high quality?
Camp4 Therapeutics Corp. (CAMP) has an earnings quality ratio of 0.37x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Camp4 Therapeutics Corp.?
Camp4 Therapeutics Corp. (CAMP) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.